Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Barone P, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020;60(6):1123-1127.

Hsu JM, Chen Z, Shore T, Gergis U, Mayer S, Phillips A, et al. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020;26(4):789-797.

Nellis ME, Saini A, Spinella PC, Davis PJ, Steiner ME, Tucci M, et al. Pediatric Plasma and Platelet Transfusions on Extracorporeal Membrane Oxygenation: A Subgroup Analysis of Two Large International Point-Prevalence Studies and the Role of Local Guidelines. Pediatr Crit Care Med. 2020;21(3):267-275.

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130(4):1653-1668.

Green DA, Zucker J, Westblade LF, Whittier S, Rennert H, Velu P, et al. Clinical Performance of SARS-CoV-2 Molecular Tests. J Clin Microbiol. 2020;58(8).

Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo MA, Datta D, et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. Nat Commun. 2020;11(1):384.

Yomtoubian S, Lee SB, Verma A, Izzo F, Markowitz G, Choi H, et al. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell Rep. 2020;30(3):755-770.e6.

Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. Eur Urol Open Sci. 2020;22:34-44.

Hwang I, Pan H, Yao J, Elemento O, Zheng H, Paik J. CIC is a critical regulator of neuronal differentiation. JCI Insight. 2020;5(9).

Kim D, Viswanathan K, Goyal A, Rao R. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2020;128(4):269-277.